PCM
LOXO

Prelude Capital Management’s Loxo Oncology, Inc LOXO Stock Holding History

Prelude Capital Management’s Portfolio LOXO Stock Details LOXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-44
Closed -$5K – 2102
2018
Q1 		$5K Sell
44
-317
-88% -$33.7K ﹤0.01% 1424
2017
Q4 		$30K Buy
361
+82
+29% +$6.84K ﹤0.01% 1048
2017
Q3 		$26K Buy
279
+9
+3% +$699 ﹤0.01% 1264
2017
Q2 		$22K Buy
+270
New +$15K ﹤0.01% 1238

Other funds holding LOXO

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Prelude Capital Management's LOXO Position: Q2 2018 in Review

Prelude Capital Management sold out of Loxo Oncology, Inc (LOXO) in Q2 2018, closing a stake of 44 shares — an estimated $5K sold.

Prelude Capital Management first reported a position in LOXO in Q2 2017 and held it in 4 quarters. The position peaked at $30K in Q4 2017. 213 funds tracked by Wall St. Rank hold LOXO as of Q2 2018.

  • Prelude Capital Management reported no remaining Loxo Oncology, Inc position as of Q2 2018 after selling out during the quarter.
  • Prelude Capital Management sold 44 Loxo Oncology, Inc shares in Q2 2018, an estimated $5K.
  • Prelude Capital Management first reported a position in Loxo Oncology, Inc in Q2 2017 and held it in 4 quarters.
  • Prelude Capital Management's Loxo Oncology, Inc position peaked at $30K in Q4 2017.
  • 213 funds tracked by Wall St. Rank held Loxo Oncology, Inc as of Q2 2018.

Based on Prelude Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.